Company Filing History:
1 out of 1,744 
1 out of 55 
1 out of 319 
Years Active: 2021
Title: Ian Morilla: Innovator in Predicting Colitis Treatment Response
Introduction
Ian Morilla is a notable inventor based in Villetaneuse, France. He has made significant contributions to the field of medical research, particularly in the area of predicting treatment responses for acute severe colitis. His innovative approach addresses a critical gap in current medical practices.
Latest Patents
Ian Morilla holds a patent for "Methods for predicting acute severe colitis treatment response." This invention provides a groundbreaking prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. The invention identifies putative mRNA targets of dysregulated microRNAs from patient biopsies. A classifier of fifteen colonic microRNAs, along with five biological values at admission, was identified, achieving a prediction accuracy of 96.6% for distinguishing responders from non-responders to steroids. Additionally, similar methods were developed to classify responders from non-responders to infliximab and cyclosporine.
Career Highlights
Throughout his career, Ian Morilla has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Paris. His work has been pivotal in advancing the understanding of treatment responses in patients suffering from acute severe colitis.
Collaborations
Ian has collaborated with notable colleagues, including Eric Ogier-Denis and Xavier Treton. Their combined expertise has contributed to the success of his research and innovations.
Conclusion
Ian Morilla's work in predicting treatment responses for acute severe colitis represents a significant advancement in medical research. His innovative methods have the potential to improve patient outcomes and transform treatment approaches in this challenging area of healthcare.